Global Glioblastoma Pipeline Insight 2021: Comprehensive Insights About 150+ Companies and 150+ Pipeline Drugs – ResearchAndMarkets.com

Global Glioblastoma Pipeline Insight 2021: Comprehensive Insights About 150+ Companies and 150+ Pipeline Drugs – ResearchAndMarkets.com




Global Glioblastoma Pipeline Insight 2021: Comprehensive Insights About 150+ Companies and 150+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Glioblastoma – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “Glioblastoma – Pipeline Insight, 2021,” report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Glioblastoma Emerging Drugs Chapters

This segment of the Glioblastoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Glioblastoma Emerging Drugs

Enzastaurin Hydrochloride: Denovo Biopharma

Enzastaurin Hydrochloride is an anti-timor drug being developed by Denovo Biopharma. Enzastaurin Hydrochloride has received orphan drug designation for the treatment of Glioblastoma. Denovo acquired global rights to enzastaurin from Lilly, including development, production and commercialization. The drug is being studied in phase III stage of development for the treatment of Glioblastoma.

Marizomib: Celgene

Marizomib is naturally occurring chemical compound, isolated from marine bacteria. This intravenously administered drug binds to and inhibits a certain protein complex involved in degradation of unneeded or damaged proteins. The subsequent abnormal accumulation of proteins is thought to inhibit tumor cell growth by signaling to the cell to stop dividing and undergo cell death. Clinical trials for Marizomib are being conducted by Celgene Corporation for the Glioblastoma. Marizomib has also recieved orphan drug designation for the treatment of patients with Glioblastoma.

2-OHOA: Laminar Pharmaceutcals

2-OHOA (2-hydroxyoleic acid) is a synthetic derivative of oleic acid which can be taken orally and is able to reach cells in the brain by crossing the Blood Brain Barrier. This drug alters the composition of the plasma membrane in cancer cells, reducing the activity of membrane-associated signaling proteins that are known to promote tumor growth. The drug is being studied in phase II/III for the treatment of Glioblastoma.

ONC-201: Oncotherapeutics

ONC201 is a highly selective antagonist of dopamine receptor D2 (DRD2) and ClpP agonist that is able to penetrate the blood-brain-barrier effectively. The drug antagonizes specific dopamine receptors that are highly expressed in tumors of the brain, particularly those that occur in its midline structures. ONC-201 is being studied in phase II for the Glioblastoma.

NVX-108: NuvOx LLC

NVX-108 is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy and the clinical trials are being conducted for NVX-108 in phase II for Glioblastoma.

CAN008: CANbridge Life Sciences

CAN008 is a glycosylation fusion protein that blocks the interaction between the CD95 receptor and its cognate ligand CD95L through binding to the CD95 ligand (CD95L). It has a unique dual mechanism of action, which can inhibit the invasive growth of tumor cells and the programmed cell death of T cells, and repair immune function. CANbridge has initiated a aphase II trials for the CAN008 for the treatment of patients with Glioblastoma.

INO5401: Inovio Pharmaceuticals

INO-5401 encodes for INOVIO’s SynCon antigens for hTERT, WT1, and PSMA, and has the potential to be a powerful cancer immunotherapy in combination with checkpoint inhibitors. The drug is being studied in phase II clinical trials in collaboration with Regeneron Pharmaceuticals.

CC-90010: Celgene Corporation

CC-90010 is a reversible oral Bromodomain and Extra-Terminal (BET) inhibitor. Bromodomain and extra-terminal (BET) proteins are epigenetic readers that regulate expression of genes involved in oncogenesis. CC-90010 clinical trials are being carried out by Celgene in phase I/II stage of development for the treatment of Glioblastoma.

Temeferon: Genenta Science

Temferon is an Investigational Advanced Therapy Medicinal Product (ATMP) consisting of autologous CD34+-TEM enriched Hematopoietic Stem and Progenitor Cells (HSPC) transduced with a Lentiviral Vector (LV) encoding the human interferon-?2 (IFN-?2) gene. Temferon is being studied in phase I/II clinical trials for the treatment of patients with Glioblastoma.

Key Topics Covered:

Introduction

Executive Summary

Glioblastoma: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Glioblastoma – Analytical Perspective

In-depth Commercial Assessment

  • Glioblastoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Glioblastoma Collaboration Deals

  • Company-Company Collaborations (Licensing/Partnering) Analysis
  • Company-University Collaborations (Licensing/Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Enzastaurin Hydrochloride: Denovo Biopharma

  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)

  • Comparative Analysis

ONC-201: Oncotherapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I/II)

  • Comparative Analysis

CC-90010: Celgene Corporation

  • Product Description
  • Research and Development
  • Product Development Activities

Preclinical Stage Products

  • Comparative Analysis

MT-201: Myeloid Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products

  • Comparative Analysis

Key Companies

Key Products

Unmet Needs

Market Drivers and Barriers

Future Perspectives and Conclusion

Analyst Views

Key Companies

Appendix

Companies Mentioned

  • Celgene Corporation
  • Oncoceutics, Inc.
  • MediciNova
  • Genenta Sceince
  • Philogen S.p.A.
  • VBI Vaccines Inc.
  • Apollomics Inc.
  • InSightec
  • Karyopharm Therapeutics Inc
  • Vaximm GmbH
  • OX2 Therapeutics
  • Laminar Pharmaceuticals
  • Ziopharm
  • Arcus Biosciences, Inc.
  • Novartis Pharmaceuticals
  • NovoCure Ltd.
  • Denovo Bipharma LLC
  • NuvOx LLC
  • Imvax
  • PharmAbcine
  • Eli Lilly and Company
  • I-Mab Biopharma Co. Ltd.
  • CNS pharmaceuticals
  • Aivita Biomedical, Inc.
  • Immunitor LLC
  • Oblato, Inc.
  • Kintara Therapeutics, Inc.
  • Jiangsu HengRui Medicine Co., Ltd.
  • CANbridge Life Sciences Ltd.
  • Myeloid Theraputics
  • Innovio Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Ocuphire Pharma
  • Peregrine Pharmaceuticals
  • Celldex Therapeutics

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/73zji7

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900